Advertisement

Gastric Cancer

, Volume 21, Issue 4, pp 579–587 | Cite as

The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis

  • Yue Hu 
  • Shan Liu 
  • Bin Lv 
Review Article

Abstract

Background

Despite extensive research on the criteria for the assessment of gastric cancer risk using the Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastritis/Intestinal-Metaplasia Assessment (OLGIM) systems, no comprehensive overview or systematic summary on their use is currently available.

Aim

To perform a systematic review and meta-analysis to assess the efficacy of the OLGA and OLGIM staging systems in evaluating gastric cancer risk.

Methods

We searched various databases, including PubMed, EMBASE, Medline, and Cochrane’s library, for articles published before March 2017 on the association between OLGA/OLGIM stages and risk of gastric cancer. Statistical analysis was performed using RevMan 5.30 and Stata 14.0, with the odds ratio, risk ratio, and 95% confidence interval as the effect measures.

Results

A meta-analysis of six case–control studies and two cohort studies, comprising 2700 subjects, was performed. The meta-analysis of prospective case–control studies demonstrated a significant association between the OLGA/OLGIM stages III/IV and gastric cancer. The Newcastle–Ottawa Scale (NOS) score reflected heterogeneity in the case–control studies on OLGA. Subgroup analysis of high-quality (NOS score ≥ 5) studies showed an association between OLGA stage III/IV and increased risk of gastric cancer; the association was also high in the remaining study with low NOS score. The association between higher stages of gastritis defined by OLGA and risk of gastric cancer was significant.

Conclusions

This correlation implies that close and frequent monitoring of such high-risk patients is necessary to facilitate timely diagnosis of gastric cancer.

Keywords

Gastric cancer Operative link on gastritis assessment Operative link on gastric intestinal metaplasia assessment stage Risk factors Meta-analysis Systematic review 

Notes

Funding

This study was funded by Natural Science Foundation of China (NSFC) (Grant numbers 81700468 and 81770535).

Ethical approval

No ethical approval or informed consent statement was required for this review article.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

10120_2018_812_MOESM1_ESM.docx (13.5 mb)
Supplementary material 1 (DOCX 13.5 MB)

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMedGoogle Scholar
  2. 2.
    Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345–89.CrossRefPubMedGoogle Scholar
  3. 3.
    Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet. 1975;2(7924):58–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13(1):2–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Shiotani A, Haruma K, Uedo N, Iishi H, Ishihara R, Tatsuta M, Kumamoto M, Nakae Y, Ishiguro S, Graham DY. Histological risk markers for non-cardia early gastric cancer. Pattern of mucin expression and gastric cancer. Virchows Arch. 2006;449(6):652–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005;36(3):228–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, van Dekken H, Meijer J, van Grieken NC, Kuipers EJ. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71(7):1150–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, Genta RM, Graham DY, Hattori T, Malfertheiner P, Nakajima S, Sipponen P, Sung J, Weinstein W, Vieth M. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40(8):650–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Rugge M, de Boni M, Pennelli G, de Bona M, Giacomelli L, Fassan M, Basso D, Plebani M, Graham DY. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinicopathological follow-up study. Aliment Pharmacol Ther. 2010;31:1104–11.PubMedGoogle Scholar
  11. 11.
    Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O’Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O’Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ, European Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74–94.CrossRefPubMedGoogle Scholar
  12. 12.
    De Re V, Orzes E, Canzonieri V, Maiero S, Fornasarig M, Alessandrini L, Cervo S, Steffan A, Zanette G, Mazzon C, De Paoli P, Cannizzaro R. Pepsinogens to distinguish patients with gastric intestinal metaplasia and helicobacter pylori infection among populations at risk for gastric cancer. Clin Transl Gastroenterol. 2016;7(7):e183.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Molaei M, Ehtiati A, Mashayekhi R, Rafizadeh M, Zojaji H, Mirsattari D, Kishani Farahani R. Gastric atrophy: use of OLGA staging system in practice. Gastroenterol Hepatol Bed Bench. 2016;9(1):25–9.PubMedPubMedCentralGoogle Scholar
  14. 14.
    El-Zimaity MH, Riddell RH, Abudayyeh S, Graham YD. Gastric atrophy diagnostic accuracy: comparison of OLGA with Baylor system. Lab Invest. 2009;89:128A.Google Scholar
  15. 15.
    Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2009) The New Castle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies on meta-analysis. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.Accessed 5 Apr 2017.
  17. 17.
    Stang A. Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Aziz O, Constantinides V, Tekkis PP, Athanasiou T, Purkayastha S, Paraskeva P, Darzi AW, Heriot AG. Laparoscopic versus open surgery for rectal cancer: a meta-analysis. Ann Surg Oncol. 2006;13(3):413–24.CrossRefPubMedGoogle Scholar
  19. 19.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMedGoogle Scholar
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMedGoogle Scholar
  21. 21.
    Satoh K, Osawa H, Yoshizawa M, Nakano H, Hirasawa T, Kihira K, Sugano K. Assessment of atrophic gastritis using the OLGA system. Helicobacter. 2008;13(3):225–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Choi I, Cho S, Kook M, Kim C, Lee J. Validaton of gastritis OLGA-staging system for gastric cancer risk in a region of high prevalence: a case-control study. Helicobacter. 2012;17:76.CrossRefGoogle Scholar
  23. 23.
    Cho SJ, Choi IJ, Kook MC, Nam BH, Kim CG, Lee JY, Ryu KW, Kim YW. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther. 2013;38(10):1292–302.CrossRefPubMedGoogle Scholar
  24. 24.
    Kodama M, Murakami K, Okimoto T, Abe H, Sato R, Ogawa R, Mizukami K, Shiota S, Nakagawa Y, Soma W, Arita T, Fujioka T. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol. 2013;48(11):1249–56.CrossRefPubMedGoogle Scholar
  25. 25.
    Tsai YC, Hsiao WH, Yang HB, Cheng HC, Chang WL, Lu CC, Sheu BS. The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer. Aliment Pharmacol Ther. 2013;37(10):969–78.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhou Y, Li HY, Zhang JJ, Chen XY, Ge ZZ, Li XB. Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer. World J Gastroenterol. 2016;22(13):3670–8.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—”ABC method”. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(7):405–14.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Shin WG, Kim HU, Song HJ, et al. Surveillance strategy of atrophic gastritis and intestinal metaplasia in a country with a high prevalence of gastric cancer. Dig Dis Sci. 2012;57(3):746–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Chinese Society of gastroenterology. Chinese national consensus on chronic gastritis. Chin J Gastroenterol. 2017;22(11):670–87.Google Scholar
  30. 30.
    Daugule I, Sudraba A, Chiu HM, Funka K, Ivanauskas A, Janciauskas D, Jonaitis L, Kiudelis G, Tolmanis I, Vanags A, Lin JT, Kupcinskas L, Leja M. Gastric plasma biomarkers and operative link for gastritis assessment gastritis stage. Eur J Gastroenterol Hepatol. 2011;23(4):302–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Quach DT, Le HM, Nguyen OT, Nguyen TS, Uemura N. The severity of endoscopic gastric atrophy could help to predict Operative Link on Gastritis Assessment gastritis stage. J Gastroenterol Hepatol. 2011;26(2):281–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Isajevs S, Liepniece-Karele I, Janciauskas D, Moisejevs G, Putnins V, Funka K, Kikuste I, Vanags A, Tolmanis I, Leja M. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch. 2014;464(4):403–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Nieminen A, Sipponen P, Kontto J, Puolakkainen P, Virtamo J, Kokkola A. OLGA and OLGIM staging systems in men with atrophic gastritis. United Eur Gastroenterol J. 2015;3(5):A296–7.Google Scholar
  34. 34.
    Rugge M, Fassan M, Pizzi M, Farinati F, Sturniolo GC, Plebani M, Graham DY. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol. 2011;17(41):4596–601.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Authors and Affiliations

  1. 1.Department of Gastroenterology, First Affiliated Hospital of ZhejiangChinese Medical UniversityHangzhouChina
  2. 2.Key Laboratory of Digestive Pathophysiology of Zhejiang Province, First Affiliated Hospital of ZhejiangChinese Medical UniversityHangzhouChina

Personalised recommendations